JP2016503293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503293A5 JP2016503293A5 JP2015540154A JP2015540154A JP2016503293A5 JP 2016503293 A5 JP2016503293 A5 JP 2016503293A5 JP 2015540154 A JP2015540154 A JP 2015540154A JP 2015540154 A JP2015540154 A JP 2015540154A JP 2016503293 A5 JP2016503293 A5 JP 2016503293A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- composition
- cdr
- binding member
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 30
- 229910052740 iodine Inorganic materials 0.000 claims description 28
- 229910052698 phosphorus Inorganic materials 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 27
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 claims description 26
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims description 26
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 24
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 24
- 150000007523 nucleic acids Chemical group 0.000 claims description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 19
- 239000013598 vector Substances 0.000 claims description 18
- 208000011580 syndromic disease Diseases 0.000 claims description 16
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 12
- 206010000496 acne Diseases 0.000 claims description 12
- 206010003246 arthritis Diseases 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 230000000737 periodic effect Effects 0.000 claims description 8
- 230000003519 ventilatory effect Effects 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 208000026326 Adult-onset Still disease Diseases 0.000 claims description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000009137 Behcet syndrome Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 4
- 206010013774 Dry eye Diseases 0.000 claims description 4
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 4
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 4
- 208000004987 Macrophage activation syndrome Diseases 0.000 claims description 4
- 206010072219 Mevalonic aciduria Diseases 0.000 claims description 4
- 208000000112 Myalgia Diseases 0.000 claims description 4
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims description 4
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims description 4
- 206010031149 Osteitis Diseases 0.000 claims description 4
- 206010031252 Osteomyelitis Diseases 0.000 claims description 4
- 201000007100 Pharyngitis Diseases 0.000 claims description 4
- 206010065159 Polychondritis Diseases 0.000 claims description 4
- 206010037575 Pustular psoriasis Diseases 0.000 claims description 4
- 206010037660 Pyrexia Diseases 0.000 claims description 4
- 208000025747 Rheumatic disease Diseases 0.000 claims description 4
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims description 4
- 208000034189 Sclerosis Diseases 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 208000024780 Urticaria Diseases 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 208000002399 aphthous stomatitis Diseases 0.000 claims description 4
- 230000031018 biological processes and functions Effects 0.000 claims description 4
- 208000018339 bone inflammation disease Diseases 0.000 claims description 4
- 208000020670 canker sore Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000030949 chronic idiopathic urticaria Diseases 0.000 claims description 4
- 206010072757 chronic spontaneous urticaria Diseases 0.000 claims description 4
- 208000024376 chronic urticaria Diseases 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 4
- 201000003265 lymphadenitis Diseases 0.000 claims description 4
- 206010072221 mevalonate kinase deficiency Diseases 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 4
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 4
- 208000009169 relapsing polychondritis Diseases 0.000 claims description 4
- 230000000552 rheumatic effect Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000004595 synovitis Diseases 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 210000004671 cell-free system Anatomy 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000001574 biopsy Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000013599 cloning vector Substances 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000014616 translation Effects 0.000 description 2
- 101001033289 Macaca fascicularis Interleukin-1 beta Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 101001076393 Rattus norvegicus Interleukin-1 beta Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722532P | 2012-11-05 | 2012-11-05 | |
| EP12007503 | 2012-11-05 | ||
| US61/722,532 | 2012-11-05 | ||
| EP12007503.1 | 2012-11-05 | ||
| PCT/EP2013/073009 WO2014068132A1 (en) | 2012-11-05 | 2013-11-05 | Binding members to il-1 beta |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018083160A Division JP6779252B2 (ja) | 2012-11-05 | 2018-04-24 | ＩＬ−１βへの結合メンバー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016503293A JP2016503293A (ja) | 2016-02-04 |
| JP2016503293A5 true JP2016503293A5 (cg-RX-API-DMAC7.html) | 2016-12-08 |
| JP6333271B2 JP6333271B2 (ja) | 2018-06-06 |
Family
ID=47146146
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540154A Active JP6333271B2 (ja) | 2012-11-05 | 2013-11-05 | ＩＬ−１βへの結合メンバー |
| JP2018083160A Expired - Fee Related JP6779252B2 (ja) | 2012-11-05 | 2018-04-24 | ＩＬ−１βへの結合メンバー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018083160A Expired - Fee Related JP6779252B2 (ja) | 2012-11-05 | 2018-04-24 | ＩＬ−１βへの結合メンバー |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US9404930B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3750917A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6333271B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102345999B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104870015B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015009892B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2888583C (cg-RX-API-DMAC7.html) |
| MX (1) | MX374817B (cg-RX-API-DMAC7.html) |
| PL (1) | PL2914287T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2711118C2 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2014068132A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3750917A1 (en) * | 2012-11-05 | 2020-12-16 | Delenex Therapeutics AG | Binding members to il-1 beta |
| US9078427B1 (en) | 2014-08-29 | 2015-07-14 | Pioneer Hi Bred International Inc | Method of storing plant embryos |
| MX368325B (es) | 2014-08-29 | 2019-09-27 | Pioneer Hi Bred Int | Metodos y dispositivos que implican matrices de aceite. |
| JP6202652B1 (ja) * | 2016-12-19 | 2017-09-27 | 株式会社ヘルスケアシステムズ | 抗エクオール抗体組成物及びその利用 |
| CN107362351B (zh) * | 2017-09-04 | 2020-11-10 | 上海市儿童医院 | Il-36r的拮抗剂在制备镇痛药物中的应用 |
| CN110818793A (zh) | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| CN113453798A (zh) | 2019-02-28 | 2021-09-28 | 埃克森美孚化学专利公司 | 催化剂组合物及前体、其制备方法和合成气转化方法 |
| TWI793503B (zh) * | 2020-01-20 | 2023-02-21 | 美商美國禮來大藥廠 | 抗IL-1β抗體 |
| AU2021384022A1 (en) | 2020-11-18 | 2023-06-01 | Novartis Ag | Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy |
| WO2022136693A1 (en) * | 2020-12-23 | 2022-06-30 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
| KR20230125239A (ko) * | 2020-12-23 | 2023-08-29 | 누맙 세러퓨틱스 아게 | 면역원성이 감소된 항체 가변 도메인 및 항체 |
| CN113908589B (zh) * | 2021-10-08 | 2022-09-27 | 天津工业大学 | 一种表面印迹抗体的疏水电荷诱导模式膜层析介质及其制备方法 |
| CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
| CN116068192A (zh) * | 2022-01-24 | 2023-05-05 | 中国农业大学 | 一种检测非洲猪瘟病毒抗体的ELISA检测试剂盒以及protein L的应用 |
| WO2024258943A1 (en) * | 2023-06-13 | 2024-12-19 | Merck Sharp & Dohme Llc | Methods of using cyclic peptides for trapping interleukin-1 beta |
| CN119735676B (zh) * | 2023-12-26 | 2025-12-16 | 华润生物医药有限公司 | 抗tslp抗体及其用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020685D0 (en) * | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| US20030026806A1 (en) | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
| US8853362B2 (en) | 2002-05-22 | 2014-10-07 | Esbatech, An Alcon Biomedical Research Unit Llc | Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same |
| CA2509136C (en) * | 2003-01-24 | 2013-10-29 | Applied Molecular Evolution, Inc. | Human il-1 beta antagonists |
| EP1851245B1 (en) * | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| PL2390267T3 (pl) | 2005-06-07 | 2013-09-30 | Esbatech A Novartis Co Llc | Stabilne i rozpuszczalne przeciwciała hamujące TNF(alfa) |
| ES2335232T3 (es) * | 2005-06-21 | 2010-03-23 | Xoma Technology Ltd. | Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta. |
| CA2727171A1 (en) * | 2008-06-06 | 2009-12-10 | Xoma Technology Ltd. | Methods for the treatment of rheumatoid arthritis |
| GB2461273A (en) | 2008-06-24 | 2009-12-30 | Seppo Haekkinen | Load monitoring system |
| GB0811574D0 (en) | 2008-06-24 | 2008-07-30 | Trillion Genomics Ltd | Characterising planar samples by mass spectrometry |
| RU2514658C2 (ru) | 2008-06-25 | 2014-04-27 | ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи | Оптимизация растворимости иммуносвязывающих средств |
| SI2752428T1 (sl) | 2008-06-25 | 2020-03-31 | Novartis Ag | Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa |
| CA2735940A1 (en) * | 2008-09-05 | 2010-03-11 | Xoma Technology Ltd. | Methods for treating or preventing il-1.beta. related diseases |
| RU2013115927A (ru) * | 2010-09-10 | 2014-10-20 | Апексиджен, Инк. | АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ |
| EP3750917A1 (en) * | 2012-11-05 | 2020-12-16 | Delenex Therapeutics AG | Binding members to il-1 beta |
-
2013
- 2013-11-05 EP EP20163414.4A patent/EP3750917A1/en not_active Withdrawn
- 2013-11-05 RU RU2015120450A patent/RU2711118C2/ru active
- 2013-11-05 CA CA2888583A patent/CA2888583C/en active Active
- 2013-11-05 BR BR112015009892-4A patent/BR112015009892B1/pt not_active IP Right Cessation
- 2013-11-05 PL PL13786473T patent/PL2914287T3/pl unknown
- 2013-11-05 WO PCT/EP2013/073009 patent/WO2014068132A1/en not_active Ceased
- 2013-11-05 MX MX2015005384A patent/MX374817B/es active IP Right Grant
- 2013-11-05 KR KR1020157013550A patent/KR102345999B1/ko not_active Expired - Fee Related
- 2013-11-05 US US14/072,165 patent/US9404930B2/en active Active
- 2013-11-05 JP JP2015540154A patent/JP6333271B2/ja active Active
- 2013-11-05 CN CN201380064089.1A patent/CN104870015B/zh not_active Expired - Fee Related
- 2013-11-05 EP EP13786473.2A patent/EP2914287B1/en active Active
-
2014
- 2014-11-05 WO PCT/EP2014/073772 patent/WO2015067636A1/en not_active Ceased
-
2016
- 2016-07-06 US US15/202,982 patent/US10077302B2/en active Active
-
2018
- 2018-04-24 JP JP2018083160A patent/JP6779252B2/ja not_active Expired - Fee Related
- 2018-08-30 US US16/118,124 patent/US10626171B2/en active Active
-
2020
- 2020-03-18 US US16/822,952 patent/US11267884B2/en active Active
-
2022
- 2022-01-28 US US17/587,751 patent/US20220220195A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503293A5 (cg-RX-API-DMAC7.html) | ||
| CN105849124B (zh) | 双重特异性抗体 | |
| JP2022160404A (ja) | ヒトｉｌ－４受容体に対する高親和性ヒト抗体 | |
| JP6779252B2 (ja) | ＩＬ−１βへの結合メンバー | |
| AU2012315474B2 (en) | Antibodies against TL1a and uses thereof | |
| TWI769537B (zh) | 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途 | |
| CN115397852B (zh) | 工程化抗il-2抗体 | |
| JP2012518425A5 (cg-RX-API-DMAC7.html) | ||
| EP4001307A1 (en) | Antibodies against il-1 beta | |
| RU2012130840A (ru) | Соединения | |
| JP2016503412A5 (ja) | Ｉｌ−６アンタゴニストおよびその使用 | |
| US12325739B2 (en) | Bispecific SARS-CoV-2 antibodies and methods of use | |
| CN104903352A (zh) | 多价结合蛋白组合物 | |
| CN109069606B (zh) | 干扰素β抗体及其用途 | |
| CN110167592A (zh) | 抗il-37抗体 | |
| CN106565840B (zh) | 抗乙肝表面抗原的抗体及其用途 | |
| TWI801425B (zh) | Il-5 抗體、其抗原結合片段及醫藥用途 | |
| WO2022100664A1 (zh) | 一种tslp抗原结合蛋白及其应用 | |
| CN114846026A (zh) | 对人il-13和il-17具有结合特异性的多特异性抗体 | |
| WO2025153079A1 (en) | Method of treatment | |
| RU2841957C1 (ru) | Сконструированные антитела против il-2 | |
| JPWO2020041537A5 (cg-RX-API-DMAC7.html) | ||
| TW202413405A (zh) | 抗體、其抗原結合片段及其藥物用途 | |
| TW202434634A (zh) | 抗IL-18Rβ抗體、其抗原結合片段及其醫藥應用 | |
| RU2852376C2 (ru) | Антитела с двойной специфичностью |